Movement Alert|Caris Life Sciences, Inc. Intraday Rise 4.46%, rebound supported by Q3 beat, raised outlook and study enrollment update

Market Focus11-11

On November 11, Caris Life Sciences, Inc. rose 4.46% in Regular Trading, trading at $25.27 per share, with turnover of $4.2085 million.

The move followed a rebound after post-earnings selling, alongside the company’s announcement that it enrolled the first patients in a genome sequencing study for myeloid cancers.

Caris Life Sciences, Inc. previously reported Q3 EPS of $0.05, above consensus expectations of $0.03 to $0.04, while revenue rose to $275.4 million from $216.8 million a year earlier and exceeded the roughly $255.4 million forecast. The company also raised full-year revenue guidance to $1.04 billion to $1.05 billion from $1.03 billion to $1.04 billion. On November 11, it additionally disclosed first-patient enrollment in a ChromoSeq study expected to enroll about 300 adults across multiple U.S. institutions, adding a fresh company-specific update as shares bounced after earlier pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment